Journal Article

Identification and Modulation of Microenvironment Is Crucial for Effective Mesenchymal Stromal Cell Therapy in Acute Lung Injury

Li, Yimin, Qiu, Haibo, Islam, Diana, Medin, Jeffery, Liu, Mingyao, Zhong, Nanshan, Luo, Alice, Wu, Sulong, Wu, Jianfeng, Huang, Yongbo, McKillop, Montey, Khang, Julie, Delsedime, Luisa, Fanelli, Vito, Laffey, John, Grassi, Alice, Li, Manshu, Liu, Xiaoqing, Han, Bing, Xu, Yonghao, Zhang, Haibo

2019

Overview

There are controversial reports on applications of mesenchymal stromal cells (MSCs) in patients with acute respiratory distress syndrome (ARDS). We hypothesized that lung microenvironment was the main determinant of beneficial versus detrimental effects of MSCs during ARDS. Lung proteome was profiled in three models of injury induced by acid instillation and/or mechanical ventilation in mice. Human gene of glutathione peroxidase-1 was delivered before MSC administration; or MSCs carrying human gene of IL-10 or hepatocyte growth factor were administered after lung injury. An inhibitory cocktail against IL-6, fibronectin, and oxidative stress was used in studies using human small airway epithelial cells and human MSCs after exposure to plasma of patients with ARDS. Distinct proteomic profiles were observed in three lung injury models. Administration of MSCs protected lung from ventilator-induced injury, whereas it worsened acid-primed lung injuries associated with fibrotic development in lung environment that had high levels of IL-6 and fibronectin along with low antioxidant capacity. Correction of microenvironment with glutathione peroxidase-1, or treatment with MSCs carrying human gene of IL-10 or hepatocyte growth factor after acid-primed injury, reversed the detrimental effects of native MSCs. Proteomic profiles obtained in the mouse models were also similarly observed in human ARDS. Treatment with the inhibitory cocktail in samples of patients with ARDS retained protective effects of MSCs in small airway epithelial cells. MSCs can be beneficial or detrimental depending on microenvironment at the time of administration. Identification of potential beneficiaries seems to be crucial to guide MSC therapy in ARDS.

• Publisher: Oxford University Press
• Subject: Animals / Cell- and Tissue-Based Therapy - methods / Disease Models, Animal / Humans / Immunotherapy / Injuries / Lungs / Mesenchymal Stem Cell Transplantation - methods / Mice / Proteomics / Respiratory distress syndrome / Respiratory Distress Syndrome, Adult - physiopathology / Respiratory Distress Syndrome, Adult - surgery